Clinical trials
Dermatomyositis clinical trials
Below are recruiting dermatomyositis clinical trials, each written for real people, not researchers. We’re tracking 39 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07486869RecruitingPhase 2
Emapalumab study for MDA5-related lung disease
This trial tests if emapalumab can help people with a serious lung condition linked to MDA5 antibodies. It may be an option for those with worsening breathing despite other treatments.
Miami, FloridaAges 18 years+ - NCT07111065RecruitingPhase 2
Fatty Acid Supplement for Dermatomyositis
This study tests whether taking a fatty acid supplement (omega-3) for 6 months can help reduce disease activity in people with dermatomyositis. Participants will also receive dietary coaching and have regular check-ups at the NIH to monitor their progress.
Bethesda, MarylandAges 18–60 - NCT06686524RecruitingPhase 1
CD19-targeted UCAR-T for refractory juvenile dermatomyositis
This trial tests a new type of immune cell therapy (UCAR-T) that targets a protein called CD19 to treat children with a severe form of juvenile dermatomyositis that hasn't responded to standard treatments. It aims to calm the overactive immune system and reduce symptoms like muscle weakness and skin rashes.
Hangzhou, ZhejiangAges 5 years+ - NCT07374107Recruiting
Patient insights for shaping myositis research
This study asks people with autoimmune muscle diseases (myositis) and their caregivers to share their experiences and insights. By joining, you help shape better research and care for myositis.
New Orleans, LouisianaAges 7 years+ - NCT07037472Recruiting
Imaging calcium deposits in dermatomyositis patients
This study uses a special imaging technique (photoacoustic/ultrasound) to look at calcium deposits under the skin in people with dermatomyositis. It aims to find patterns that help doctors understand the condition and track how well treatments work.
BeijingAges 18–80 - NCT02945345Recruiting
Test how skin scores change in cutaneous dermatomyositis
This study looks at how well skin symptoms improve in adults with cutaneous dermatomyositis by using a specific skin-scoring tool. The results may help doctors better measure treatment response and guide care.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06154252RecruitingPhase 2/Phase 3
Study of CABA-201 for active myositis in adults and children
This trial tests a new treatment called CABA-201, which uses your own immune cells modified to attack the overactive cells causing myositis. It is for people with active disease that hasn't improved enough with standard therapies.
Orange, CaliforniaAges 6–75 - NCT06203249Recruiting
Exploring lung health and immune system in a rare muscle disease
This trial looks at how the immune system and tiny organisms in the lungs may affect a rare condition called anti-MDA5 positive dermatomyositis, which can cause serious lung disease. It may help doctors understand why some patients get worse quickly and how to better treat them.
Beijing, Beijing MunicipalityAges 18–100 - NCT06569472RecruitingPhase 1
CAR-T cell therapy for tough juvenile dermatomyositis
This trial tests a treatment using your own immune cells, modified to target a protein called CD19, for children and teens with juvenile dermatomyositis that hasn't gotten better with standard treatments. The goal is to see if this therapy can help calm the inflammation and improve symptoms.
Hangzhou, ZhejiangAges 5–17 - NCT07345949Recruiting
Study of skin inflammation in dermatomyositis
This trial looks at a type of skin inflammation called panniculitis that can happen in people with dermatomyositis. The goal is to learn more about this condition so that better treatments can be developed.
StrasbourgAges 1 year+ - NCT07265999Recruiting
Severity factors of dermatomyositis in Caribbean patients
This study looks at what makes dermatomyositis more severe in people of Caribbean background living in Guadeloupe. By understanding these factors, doctors may better manage this rare muscle and skin disease.
Pointe-à-PitreAges 16 years+ - NCT07160205RecruitingPhase 2/Phase 3
Study of ULSC for dermatomyositis and polymyositis
This trial tests a new treatment called ULSC to see if it can improve muscle strength and skin symptoms, and help reduce steroid use in people with dermatomyositis or polymyositis. It may be an option if standard treatments haven't worked well enough.
Gainesville, FloridaAges 18 years+ - NCT06298019RecruitingPhase 1
CAR T-cell therapy for tough dermatomyositis
This study tests a new immune therapy called CAR T-cells (KYV-101) for people with active, tough-to-treat dermatomyositis. It aims to see if the treatment is safe and can reduce muscle weakness and skin rash.
Palo Alto, CaliforniaAges 25–72 - NCT06857240RecruitingPhase 2
Ruxolitinib cream for stubborn skin in dermatomyositis
This trial tests a cream called ruxolitinib for people with dermatomyositis whose skin symptoms haven't improved with standard treatments. It aims to see if this cream can reduce rash and activity when added to your current medications.
Cleveland, OhioAges 18–89 - NCT06455449RecruitingPhase 3
Injectable anifrolumab for polymyositis or dermatomyositis
This study tests a new injectable medicine (anifrolumab) added to your usual treatments for polymyositis or dermatomyositis. It may help reduce disease activity if you have moderate to severe symptoms and are already on stable therapy.
Phoenix, ArizonaAges 18–75 - NCT06438679Enrolling by invitationPhase 4
3T therapy for MDA5-positive dermatomyositis with lung involvement
This trial tests a treatment called 3T therapy for people with MDA5-positive dermatomyositis, a rare autoimmune disease that affects the skin, muscles, and often the lungs. The goal is to see if 3T therapy can help control the disease and improve lung function.
Hangzhou, ZhejiangAges 18 years+ - NCT04972760RecruitingPhase 3
Baricitinib for active dermatomyositis in adults
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
ParisAges 18–64 - NCT01276470Recruiting
Study of environmental triggers in anti-synthetase syndrome
This study looks for environmental risk factors that may be linked to anti-synthetase syndrome, a type of inflammatory muscle disease. It compares people with the condition to carefully matched people without it, using questionnaires, blood samples, and lung imaging when needed.
Miami, FloridaAges 2–100 - NCT06462768Recruiting
Study of immune cell activity in systemic sclerosis
This study looks at a specific type of immune cell activity (called neutrophil extracellular traps) in the blood of people with systemic sclerosis, other connective tissue diseases, and healthy volunteers. It aims to understand how these cells may be involved in the disease and could lead to better treatments.
ReimsAges 18 years+ - NCT07558850Recruiting
CAR-T Cell Therapy for Treatment-Resistant Autoimmune Diseases
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
Nanjing, JiangsuAges 18–70 - NCT06732674Recruiting
Home-based care for lung disease in rheumatic conditions
This trial tests whether people with lung disease caused by a rheumatic condition can safely manage their care at home using a smartphone or tablet. It aims to see if home monitoring is as effective as in-person visits for keeping your lungs healthy.
OsloAges 18 years+ - NCT07403188Recruiting
Long-Term Follow-Up Study for KYV-101 Participants
This long-term follow-up study checks on the health and safety of people who have already received the experimental cell therapy KYV-101 in a previous clinical trial. It is a way for them to be monitored over time without any additional treatments.
Denver, ColoradoAges 18 years+ - NCT07377058Recruiting
Tocilizumab study for anti-MDA5 positive dermatomyositis
This trial tests if adding the drug tocilizumab to standard therapy helps people with a rare type of dermatomyositis (anti-MDA5 positive) that often affects the lungs. It compares tocilizumab to a placebo to see if it can improve symptoms and lung function.
Beijing, Beijing MunicipalityAges 18–65 - NCT06919380RecruitingPhase 1
Mist from stem cell byproducts for autoimmune lung disease
This study tests a new type of treatment using a mist (nebulized) made from stem cell byproducts to see if it can safely help people with a rare autoimmune lung disease. It is for patients with anti-MDA5 positive dermatomyositis who have a fast-progressing lung condition.
Guangzhou, GuangdongAges 18–75
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Dermatomyositis trials by city
Studies with a site in or near these metro areas.
Dermatomyositis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for dermatomyositis?
- Yes. Clin2 currently lists 39 recruiting dermatomyositis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a dermatomyositis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a dermatomyositis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.